ANIX · Anixa Biosciences Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.10M | - | $1.05M | $1.32M | $1.55M | - | $1.93M | $1.65M | $1.35M | - |
| SG&A | $1.61M | - | $1.38M | $1.68M | $1.83M | - | $1.67M | $1.82M | $2.26M | - |
| Total Operating Expenses | $2.72M | - | $2.44M | $3.00M | $3.39M | - | $3.59M | $3.47M | $3.61M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($2.72M) | - | ($2.44M) | ($3.00M) | ($3.39M) | - | ($3.59M) | ($3.47M) | ($3.61M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($2.56M) | - | ($2.26M) | ($2.79M) | ($3.18M) | - | ($3.28M) | ($3.14M) | ($3.25M) | - |
| EPS - Basic | ($0.08) | - | ($0.07) | ($0.09) | ($0.10) | - | ($0.10) | ($0.10) | $0.10 | - |
| EPS - Diluted | ($0.08) | - | ($0.07) | ($0.09) | ($0.10) | - | ($0.10) | ($0.10) | $0.08 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.55M | $1.24M | $1.50M | $1.91M | $1.05M | $1.27M | $1.23M | $995.0K | $998.0K | $915.0K |
| Accounts Receivable | - | - | - | - | - | $173.0K | $410.0K | $218.0K | $391.0K | $270.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $148.0K | $165.0K | $276.0K | $284.0K | $600.0K | $525.0K | $302.0K | $215.0K | $364.0K | $206.0K |
| Current Assets | $15.05M | $15.89M | $17.45M | $16.77M | $18.69M | $21.36M | $22.67M | $24.21M | $25.22M | $25.36M |
| Total Assets | $15.23M | $16.08M | $17.65M | $16.98M | $18.91M | $21.59M | $22.91M | $24.36M | $25.37M | $25.52M |
| Current Liabilities | $1.24M | $1.97M | $2.07M | $1.89M | $2.00M | $2.50M | $2.00M | $1.68M | $1.66M | $2.03M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.39M | $2.13M | $2.24M | $2.07M | $2.19M | $2.70M | $2.22M | $1.77M | $1.77M | $2.15M |
| Stockholders' Equity | $15.08M | $15.16M | $16.59M | $16.07M | $17.85M | $20.00M | $21.77M | $23.62M | $24.61M | $24.34M |
| Retained Earnings | ($254.24M) | ($251.68M) | ($248.98M) | ($246.72M) | ($243.93M) | ($240.75M) | ($237.87M) | ($234.59M) | ($231.45M) | ($228.20M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.61M) | - | - | - | ($2.90M) | - | - | - | ($2.31M) | - |
| Investing Cash Flow | $1.23M | - | - | - | $2.70M | - | - | - | $129.0K | - |
| Financing Cash Flow | $1.69M | - | - | - | ($17.0K) | - | - | - | $2.26M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -16.8% | - | -12.8% | -16.4% | -16.8% | - | -14.3% | -12.9% | -12.8% | - |
| Return on equity | -17.0% | - | -13.6% | -17.4% | -17.8% | - | -15.1% | -13.3% | -13.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 12.18 | 8.08 | 8.45 | 8.89 | 9.35 | 8.54 | 11.31 | 14.40 | 15.19 | 12.50 |
| Quick ratio | 12.18 | 8.08 | 8.45 | 8.89 | 9.35 | 8.54 | 11.31 | 14.40 | 15.19 | 12.50 |
| Cash ratio | 1.25 | 0.63 | 0.72 | 1.01 | 0.53 | 0.51 | 0.61 | 0.59 | 0.60 | 0.45 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.01 | 1.06 | 1.06 | 1.06 | 1.06 | 1.08 | 1.05 | 1.03 | 1.03 | 1.05 |
| Liabilities / Assets | 0.09 | 0.13 | 0.13 | 0.12 | 0.12 | 0.13 | 0.10 | 0.07 | 0.07 | 0.08 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | 56.8x | - |
| P / B | 6.7x | - | 6.0x | 5.6x | 5.2x | - | 0.0x | 0.0x | 0.0x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 19.8% | - | 32.2% | 13.4% | 6.2% | - | -26.3% | -35.4% | -41.2% | - |
| Net income growth (YoY) | 19.4% | - | 31.1% | 11.1% | 2.2% | - | -30.5% | -37.2% | -40.2% | - |
| EPS growth (YoY) | 20.0% | - | 30.0% | 10.0% | - | - | -25.0% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -15.5% | -24.2% | -23.8% | -32.0% | -27.4% | -17.8% | -14.7% | -11.9% | -11.5% | -16.2% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Anixa Biosciences Inc against the 5 most active filers in the same SIC group.